Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions
- PMID: 11186154
- DOI: 10.1097/00002371-200011000-00007
Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions
Abstract
The authors report that the nature of the T-cell-receptor--derived signal in normal CD4+ T cells can induce interleukin-2 (IL-2) secretion or perforin-mediated cytolytic activity. Normal human T cells were genetically modified to express the tumor antigen specific chimeric immune receptor, CC49-zeta. The CC49-zeta chimeric immune receptor is comprised of the intracellular signaling domains of the TCR CD3zeta protein fused to the single chain scFv of the humanized CC49 antibody, which binds the pan-adenocarcinoma tumor antigen TAG-72. Patient-specific T cells genetically modified to express the CC49-zeta receptor have been used in patients with colon cancer. The authors report that both CD4 and CD8 T cells expressing the CC49-zeta receptor mediated the major histocompatibility complex-unrestricted lysis of TAG-72--expressing tumor cells with comparable efficiency. However, although the CC49-zeta receptor mediated target cell lysis, it did not support the production of IL-2, even in the presence of CD28 stimulation. Robust IL-2 secretion and T-cell proliferation were observed when the same CD4 CC49-zeta T cells were stimulated through the CD28 receptor and endogenous T-cell receptor. These results indicate that CD4 T lymphocytes possess the capacity to act as both cytolytic and helper T cells and that this difference in effector function is controlled by the nature of the T-Cell receptor--derived signals.
Similar articles
-
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.Blood. 2002 Nov 1;100(9):3155-63. doi: 10.1182/blood-2002-04-1041. Blood. 2002. PMID: 12384413
-
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.J Immunol. 2002 Nov 15;169(10):5780-6. doi: 10.4049/jimmunol.169.10.5780. J Immunol. 2002. PMID: 12421958
-
Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.J Immunol. 1992 Jan 1;148(1):285-91. J Immunol. 1992. PMID: 1345787
-
Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.Ann Ist Super Sanita. 1990;26(3-4):369-84. Ann Ist Super Sanita. 1990. PMID: 2151107 Review.
-
Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases.Immunol Today. 1994 May;15(5):225-34. doi: 10.1016/0167-5699(94)90248-8. Immunol Today. 1994. PMID: 8024683 Review.
Cited by
-
Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.Cancer Biother Radiopharm. 2012 Dec;27(10):711-8. doi: 10.1089/cbr.2012.1246. Epub 2012 Sep 18. Cancer Biother Radiopharm. 2012. PMID: 22988969 Free PMC article.
-
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15. doi: 10.1158/1078-0432.CCR-06-1183. Clin Cancer Res. 2006. PMID: 17062687 Free PMC article. Clinical Trial.
-
The promise and potential pitfalls of chimeric antigen receptors.Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Curr Opin Immunol. 2009. PMID: 19327974 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials